<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Track</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 1-Jan | 6:00-7:00 AM | New Practices in Early Phase Drug Discovery | 3D-Micro Tissues in Translational Toxicology and Disease Modelling | Armin Wolf, PhD  
Chief Scientific Officer, InSphero AG |
| 1-Jan | 6:00-7:00 AM | Advancement of Biomarkers in Drug Development | CK18 as a Biomarker in NASH Clinical Trials | Jessica Tuohy, PhD  
Scientific Product Manager, DiaPharma Group, Inc. |
| 1-Jan | 6:00-7:00 AM | New Practices in Early Phase Drug Discovery | Generation of expanded primary liver cells | Astrid Nörenberg, PhD  
Managing Director, upcyte technologies GmbH |
| 1-Jan | 6:00-7:00 AM | New Practices in Early Phase Drug Discovery | Human Tissue models for better therapies | Sebastiaan Trietsch, PhD  
Chief Technology Officer, Mimetas -The Organ on a Chip Company |
| 1-Jan | 6:00-7:00 AM | Advancement of Biomarkers in Drug Development | Measuring What Matters: Proliferation and Cell Death Biomarkers for Oncology Research | Olivia Stricker, PhD  
Commercial Business Development Manager, Diapharma Group, Inc. |
| 1-Jan | 6:00-7:00 AM | New Practices in Early Phase Drug Discovery | Microfabricated Human Liver Tissues for Drug Development | Salman Khetani, PhD  
Associate Professor, Department of Bioengineering, University of Illinois at Chicago |
| 1-Jan | 6:00-7:00 AM | New Practices in Early Phase Drug Discovery | Microphysiological Systems for Human Focused Drug Discovery | Tomasz Kostrzewski, PhD  
Director, Biology, CN Bio Innovations Limited |
| 1-Jan | 6:00-7:00 AM | New Practices in Early Phase Drug Discovery | Organoids: A Revolutionary New Tool for Drug Screening | Rekha Pal, PhD  
Director, Scientific Engagement, Crown Bioscience, Inc. |
| 1-Jan | 6:00-7:00 AM | Modern Approaches to Clinical Development | Uncovering the mechanism of stress-resistant DNA replication in cancer cells using a modern single-molecule technique | Chames Kermi, PhD, PharmD  
Postdoctoral Fellow, Chemical and Systems Biology, Stanford University School of Medicine |
| 1-Jan | 6:00-7:00 AM | New Practices in Early Phase Drug Discovery | Using 3D cell culture models and high content confocal imaging to evaluate efficacy and expose toxic liabilities in the drug development pipeline | Erin Edwards, PhD  
Head of Services, Visikol, Inc. |
| 1-Jan | 6:00-7:00 AM | Advancement of Biomarkers in Drug Development | Vancomycin: How might Urinary Biomarkers and Precision Dosing create Precision Medicine for the most frequently utilized antibiotic in the hospital? | Marc H. Scheetz, PharmD, MSc, FCCP, BCPS AQ-ID  
Professor, Midwestern University in the Chicago College of Pharmacy, Director of the Pharmacometric Center of Excellence at Midwestern University |
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>26-Feb</td>
<td>6:00-7:00 AM</td>
<td>Modern Approaches to Clinical Development</td>
<td>Keynote Presentation: Discovery and Development of a Novel First-in-Class Resuscitative Agent</td>
<td>Professor Anil Gulati, MD, PhD Chairman &amp; Chief Executive Officer of Pharmazz, Inc.; Adjunct Professor, Colleges of Pharmacy and Graduate Studies, Midwestern University; Department of Bioengineering, University of Illinois</td>
</tr>
<tr>
<td>26-Feb</td>
<td>7:30-8:30 AM</td>
<td>Modern Approaches to Clinical Development</td>
<td>Keynote Presentation: Emerging Drug Combinations: Evolution From Pre-Clinical Discovery to Clinical Development</td>
<td>Khyati Shah, PhD Post Doctoral Research Scholar at University of California, San Francisco</td>
</tr>
<tr>
<td>26-Feb</td>
<td>9:00-10:00 AM</td>
<td>Modern Approaches to Clinical Development</td>
<td>CRISPR Based Screening: Advantages of Transcriptional Activators and Inhibitors</td>
<td>Andrew Ravanelli, PhD Senior R&amp;D Scientist, Genome and Epigenome Editing, MilliporeSigma</td>
</tr>
<tr>
<td>26-Feb</td>
<td>10:30-11:30 AM</td>
<td>Modern Approaches to Clinical Development</td>
<td>QIAGEN CLC Genomics Workbench 20 - scalable software for NGS data analysis</td>
<td>Leif Schauser, PhD Director, Global Product Management, QIAGEN</td>
</tr>
<tr>
<td>26-Feb</td>
<td>12:00-1:00 PM</td>
<td>New Practices in Early Phase Drug Discovery</td>
<td>Characterizing the role of B cells in Response to Immunotherapy with the NanoString GeoMx Platform</td>
<td>Sarah Warren, PhD Senior Director of Advanced Applications, NanoString Technologies</td>
</tr>
<tr>
<td>26-Feb</td>
<td>1:30-2:30 PM</td>
<td>New Practices in Early Phase Drug Discovery</td>
<td>Automated cell separation for drug discovery assays</td>
<td>Josh Mahllos, PhD Senior Marketing Product Manager, Miltenyi Biotec</td>
</tr>
</tbody>
</table>